EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacometabolomics Enables Real-World Drug Metabolism Sciences

Fleur B Nijdam iD, Marieke A J Hof iD, Hans Blokzijl iD, Stephan J L Bakker iD, Eelko Hak, Gérard Hopfgartner, Frank Klont iD, On Behalf Of The TransplantLines Investigators

Metabolites · 10.01.2025 · 15 (1) · 39

DOI: 10.3390/metabo15010039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Metabolites, online erschienen am 10.01.2025. Verfasst von Fleur B Nijdam und 7 weiteren Autor:innen. Beteiligte Einrichtung: Unit of PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 …. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union - Horizon 2020 Research and Innovation Program - Marie Skłodow-ska-Curie Actions, Netherlands Organization for Scientific Research NWO - domain Applied and Engineering Sciences, European Union’s Horizon 2020 Research and Innovation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Pharmacogenomics (PGx) has revolutionized personalized medicine, notably by predicting drug responses through the study of the metabolic genotype of drug-metabolizing enzymes. However, these genotypes rely heavily on the availability and completeness of drug metabolism information and do not account for (all) “phenoconversion” factors, like drug–drug interactions and comorbidities. To address these limitations, a more phenotypic approach would be desirable, for which pharmacometabolomics (PMx) could be useful by studying and elucidating drug metabolism in patient samples, such as blood and urine.

Methods

This study explored the potential of PMx to analyze real-world drug metabolite profiles of the extensively studied drug cyclosporine (CsA) using 24-h urine samples from 732 kidney and 350 liver transplant recipients included in the TransplantLines Biobank and Cohort Study (NCT identifier NCT03272841). Detected metabolites were matched with existing information on CsA metabolism gathered through a comprehensive literature review, aiming to confirm previously reported metabolites and identify potentially unreported ones.

Results

Our analyses confirmed the urinary presence of CsA and six known metabolites. Additionally, we detected three known metabolites not previously reported in urine and identified one unreported metabolite, potentially suggesting the involvement of glutathione conjugation. Lastly, the observed metabolic patterns showed no notable differences between kidney and liver transplant recipients.

Conclusions

Our findings demonstrate the potential of PMx to enhance the understanding of drug metabolism, even for well-studied compounds such as CsA. Moreover, this study highlights the value of PMx in real-world drug metabolism research and its potential to complement PGx in advancing personalized medicine.

Schlagwörter

Stichwörter der Autor:innen

drug metabolismhumanpersonalized medicinepharmacogenomicspharmacometabolomicsreal-world

Autor:innen und Institutionen

  • Unit of PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
  • Department of Analytical Biochemistry, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
  • Department of Gastroenterology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands.
  • Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands.
  • Life Sciences Mass Spectrometry, Department of Inorganic and Analytical Chemistry, University of Geneva, Quai Ernest Ansermet 24, 1211 Geneva, Switzerland.
  • Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands.

ORCID-Profile: Fleur B Nijdam, Marieke A J Hof, Hans Blokzijl, Stephan J L Bakker, Frank Klont

Förderung

  • European Union - Horizon 2020 Research and Innovation Program - Marie Skłodow-ska-Curie Actions
  • Netherlands Organization for Scientific Research NWO - domain Applied and Engineering Sciences
  • European Union’s Horizon 2020 Research and Innovation Program
  • the Netherlands Organization for Scientific Research NWO (domain Applied and Engineering Sciences)

Zitieren

APA

Nijdam, F. B., Hof, M. A. J., Blokzijl, H., Bakker, S. J. L., Hak, E., Hopfgartner, G., Klont, F., & On Behalf Of The TransplantLines Investigators (2025). Pharmacometabolomics Enables Real-World Drug Metabolism Sciences. Metabolites, 15(1), 39. https://doi.org/10.3390/metabo15010039

Vancouver

Nijdam FB, Hof MAJ, Blokzijl H, Bakker SJL, Hak E, Hopfgartner G, et al. Pharmacometabolomics Enables Real-World Drug Metabolism Sciences. Metabolites. 2025;15(1):39. doi:10.3390/metabo15010039

BibTeX
@article{Nijdam2025,
  author = {Nijdam, Fleur B and Hof, Marieke A J and Blokzijl, Hans and Bakker, Stephan J L and Hak, Eelko and Hopfgartner, Gérard and Klont, Frank and On Behalf Of The TransplantLines Investigators},
  title = {Pharmacometabolomics Enables Real-World Drug Metabolism Sciences},
  journal = {Metabolites},
  year = {2025},
  volume = {15},
  number = {1},
  pages = {39},
  doi = {10.3390/metabo15010039}
}
Kostenlos starten →